▁in ▁ster oid ogen esis , ▁and ▁direct ▁binding ▁to ▁and ▁occupation ▁of ▁ster oid ▁h orm one ▁car rier ▁prote ins ▁and ▁consequ ent ▁disp lacement ▁of ▁ster oid ▁h orm ones ▁from ▁these ▁prote ins . ▁The ▁drug ▁is ▁character ized ▁as ▁a ▁weak ▁and ro gen ▁and ▁an abol ic , ▁a ▁weak ▁pro gest ogen , ▁a ▁weak ▁ant ig on ad otrop in , ▁a ▁weak ▁ster oid ogen esis ▁in hib itor , ▁and ▁a ▁functional ▁anti estro gen . ▁ ▁Mod ulation ▁of ▁ster oid ▁h orm one ▁re cept ors ▁Dan az ol ▁is ▁described ▁as ▁a ▁possess ing ▁high ▁aff inity ▁for ▁the ▁and ro gen ▁re ceptor ▁( AR ), ▁moder ate ▁aff inity ▁for ▁the ▁pro g ester one ▁re ceptor ▁( PR ) ▁and ▁gl uc oc ort ico id ▁re ceptor ▁( GR ), ▁and ▁poor ▁aff inity ▁for ▁the ▁est ro gen ▁re ceptor ▁( ER ). ▁As ▁an ▁and ro gen , ▁dan az ol ▁is ▁described ▁as ▁weak , ▁being ▁about ▁ 2 0 0 - fold ▁less ▁pot ent ▁than ▁test oster one ▁in ▁bio ass ays . ▁The ▁drug ▁can ▁act ▁as ▁both ▁an ▁ag on ist ▁and ▁ant agon ist ▁of ▁the ▁PR ▁depending ▁on ▁the ▁bio ass ay , ▁indicating ▁that ▁it ▁could ▁be ▁regarded ▁as ▁a ▁select ive ▁pro g ester one ▁re ceptor ▁mod ulator ▁( SP R M ). ▁Although ▁the ▁aff inity ▁and ▁effic acy ▁of ▁dan az ol